Claims

1. A composition for use in the treatment of a disorder modulated by a GPR120 receptor, the composition comprising a therapeutically effective amount of a compound selected from the group consisting of:

3-{4-[(5-Chloro-2-ethyl-1-benzofuran-7-yl)methoxyl]-2,3-dimethylphenyl}propanoic acid;

3-(2,3-Dimethyl-4-{[2-methyl-5-(trifluoromethoxy)-1-benzofuran-7-yl]methoxy}phenyl)propanoic acid;

3-(7-{[2-Methyl-5-(trifluoromethoxy)-1-benzofuran-7-yl]methoxy}-2,3-dihydro-1H-inden-4-yl)propanoic acid;

3-{4-[(5-Chloro-2-methyl-1-benzofuran-7-yl)methoxyl]-2,3-dimethylphenyl}propanoic acid;

3-{4-[(5-Chloro-2,6-dimethyl-1-benzofuran-7-yl)methoxyl]-2,3-dimethylphenyl}propanoic acid;

3-(4-{[2-(2-Fluoroethenyl)-5-(trifluoromethoxy)-1-benzofuran-7-yl]methoxy}-2,3-dimethylphenyl)propanoic acid;

3-{4-[(6-Chloro-2-methyl-1,3-benzothiazol-4-yl)methoxyl]-2,3-dimethylphenyl}propanoic acid; and pharmaceutically acceptable salts thereof.

2. The composition of claim 1, wherein the disorder modulated by the GPR120 receptor is selected from the group consisting of obesity, obesity-related disorders, impaired oral glucose tolerance, insulin resistance, Type II diabetes mellitus, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity-induced inflammation, osteoporosis, and combinations of the foregoing.

3. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is Type II diabetes mellitus.

4. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is obesity.

5. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is dyslipidemia.

6. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is metabolic syndrome.

7. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is elevated LDL.

8. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is obesity-induced inflammation.

9. The composition of claim 2, wherein the disorder modulated by the GPR120 receptor is osteoporosis.

10. The composition of claim 2, wherein the obesity-related disorder is an obesity-related cardiovascular disorder.

11. A composition for use in the treatment of a disorder modulated by a GPR120 receptor, the composition comprising a therapeutically effective amount of 3-(2,3-Dimethyl-4-{[2-methyl-5-(trifluoromethoxy)-1-benzofuran-7-yl]methoxy}phenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

12. The composition of claim 11, wherein the disorder modulated by the GPR120 receptor is selected from the group consisting of obesity, obesity-related disorders, impaired oral glucose tolerance, insulin resistance, Type II diabetes mellitus, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity-induced inflammation, osteoporosis, and combinations of the foregoing.

13. The composition of claim 12, wherein the disorder modulated by the GPR120 receptor is Type II diabetes mellitus.

14. The composition of claim 12, wherein the disorder modulated by the GPR120 receptor is obesity or dyslipidemia.

15. The composition of claim 12, wherein the disorder modulated by the GPR120 receptor is impaired oral glucose tolerance or insulin resistance.

16. The composition of claim 12, wherein the disorder modulated by the GPR120 receptor is selected from the group consisting of obesity-related disorders, elevated LDL, elevated triglycerides, obesity-induced inflammation, and osteoporosis.

17. The composition of claim 12, wherein the obesity-related disorder is an obesity-related cardiovascular disorder.